A detailed history of Nisa Investment Advisors, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 10,790 shares of ALLO stock, worth $24,493. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,790
Previous 10,767 0.21%
Holding current value
$24,493
Previous $25,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$2.08 - $3.5 $47 - $80
23 Added 0.21%
10,790 $30,000
Q2 2024

Jul 19, 2024

BUY
$2.23 - $4.38 $19,476 - $38,254
8,734 Added 429.61%
10,767 $25,000
Q1 2024

May 01, 2024

BUY
$2.92 - $5.63 $37 - $73
13 Added 0.64%
2,033 $9,000
Q4 2023

Jan 25, 2024

SELL
$2.28 - $3.5 $182 - $280
-80 Reduced 3.81%
2,020 $6,000
Q3 2023

Nov 02, 2023

BUY
$3.17 - $5.96 $443 - $834
140 Added 7.14%
2,100 $6,000
Q2 2023

Aug 11, 2023

BUY
$4.53 - $6.74 $6,342 - $9,436
1,400 Added 250.0%
1,960 $9,000
Q4 2022

Feb 02, 2023

SELL
$5.62 - $11.11 $382 - $755
-68 Reduced 10.83%
560 $4,000
Q3 2022

Nov 07, 2022

BUY
$10.32 - $17.28 $701 - $1,175
68 Added 12.14%
628 $6,000
Q1 2022

Apr 29, 2022

BUY
$7.65 - $15.29 $4,284 - $8,562
560 New
560 $5,000
Q4 2021

Feb 03, 2022

SELL
$13.13 - $24.52 $7,352 - $13,731
-560 Closed
0 $0
Q4 2020

Jan 25, 2021

SELL
$25.24 - $43.45 $31,549 - $54,312
-1,250 Reduced 69.06%
560 $14,000
Q3 2020

Oct 20, 2020

BUY
$32.38 - $44.96 $43,713 - $60,696
1,350 Added 293.48%
1,810 $68,000
Q2 2020

Jul 27, 2020

BUY
$18.39 - $54.04 $8,459 - $24,858
460 New
460 $20,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.